Toxicokinetics and hydrolysis of artelinate and artesunate in malaria-infected rats.
Comparative toxicokinetic (TK) and hydrolysis studies of intravenously administered two new antimalarial agents, artelinate (AL) and artesunate (AS), were performed in malaria-infected rats using three daily equimolar doses (96 micromoles/kg). The TK evaluation was related to select one drug for severe malaria treatment in U.S. Army. Drug concentration of AS with daily dose of 36.7 mg/kg was one-third less on day 3 than on day 1, which resembled its active metabolite, dihydroartemisinin (DHA), suggesting an autoinduction of hepatic drug-metabolizing enzymes for AS. The results were similar to other artemisinin drugs, but not for AL. TK parameters of AL were very comparable from day 1 to day 3 at same AS molecular dose at 40.6 mg/kg. AS is the prodrug of DHA with the DHA/AS ratio of 5.26 compared to the ratio of 0.01 for DHA/AL. Other TK parameters revealed that the total AUC1-3 days (84.4 microg.h ml-1) of AL was fivefold higher than that of AS (15.7 microg.h ml-1 of AS plus DHA). The elimination half-life of AL (7.1 h) was much longer than that of AS (0.36 h) or DHA (0.72 h). The remarkable alteration of the TK shape of AL may be caused by poor conversion rates to DHA and an enterohepatic circulation, which is confirmed by the present TK and tissue distribution studies. Compared to AS, higher drug exposure levels and longer exposure time of AL in the rat blood may be the cause of its increased toxicity.
Li
Qigui
Q
Division of Experimental Therapeutics, Walter Reed Army Institute of Research, Silver Spring, Maryland 20910-7500, USA. qigui.li@na.amedd.army.mil
Xie
Lisa H
LH
Si
Yuanzheng
Y
Wong
Elaine
E
Upadhyay
Ravi
R
Yanez
Danielle
D
Weina
Peter J
PJ
D000818:Animals; D000962:Antimalarials / Q000493:pharmacokinetics* / Q000627:therapeutic use; D019540:Area Under Curve; D037621:Artemisinins / Q000097:blood / Q000378:metabolism / Q000493:pharmacokinetics* / Q000627:therapeutic use; D000077332:Artesunate; D004195:Disease Models, Animal; D006207:Half-Life; D006868:Hydrolysis; D007275:Injections, Intravenous; D008099:Liver / Q000187:drug effects / Q000201:enzymology; D008288:Malaria / Q000097:blood / Q000378:metabolism* / Q000469:parasitology; D008657:Metabolic Clearance Rate; D010962:Plasmodium berghei; D011355:Prodrugs / Q000493:pharmacokinetics*; D051381:Rats; D017207:Rats, Sprague-Dawley; D012717:Sesquiterpenes / Q000097:blood / Q000378:metabolism / Q000493:pharmacokinetics* / Q000627:therapeutic use; D014018:Tissue Distribution
D000962:Antimalarials; D037621:Artemisinins; D011355:Prodrugs; D012717:Sesquiterpenes; C062768:artelinic acid; D000077332:Artesunate; C039060:artenimol